Latest news
24 January 2023
FDA accepts Drug Master File, signifying a new milestone for Touchlight’s enzymatic doggybone DNA technology
Drug Master File simplifies the U.S. regulatory process for utilising Touchlight’s doggybone DNA and accelerates regulatory filings. doggybone DNA is the first enzymatic DNA platform with a Drug Master File, representing a significant step towards regulatory adoption. Hampton, UK, 24 January 2023 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced … Continued
7 December 2022
Touchlight and Odimma Therapeutics announce clinical material supply agreement to develop personalised cancer therapy utilising doggybone DNA
Touchlight and Odimma have entered into an agreement to develop and supply clinical material for Odimma’s neoantigen program Hampton, UK, 7 December 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announces a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalised cancer immunotherapy. … Continued
29 November 2022
Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform
Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses. Hampton, UK – 29 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development … Continued
15 November 2022
Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform
Hampton, UK, 15 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a patent license agreement with Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids. Under the license agreement, Voyager gains rights to Touchlight’s DNA technology for use in … Continued
6 September 2022
Lonza and Touchlight collaborate on end-to-end mRNA offering
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNA). Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability. Customers can gain access to Touchlight’s dbDNA as an integral part of Lonza’s offering, benefiting from end-to-end mRNA … Continued
22 August 2022
Touchlight awarded ILAP for therapeutic DNA vaccine
Touchlight has been officially awarded an Innovation Passport through Innovative Licensing and Access Pathway (ILAP) for its therapeutic DNA vaccine, a vaccine that targets head and neck squamous cell carcinoma (HNSCC). ILAP is a novel pathway formed by the MHRA, NICE, SMC, and the AWTTC, supporting innovative approaches to the safe, timely and efficient development … Continued
6 July 2022
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies
Pfizer and Touchlight agree to patent license for Pfizer to utilise rapid, scalable, enzymatic doggybone DNA (dbDNA) in Pfizer’s clinical and commercial manufacture of its mRNA vaccines, therapeutics, and gene therapies Agreement includes upfront payment, potential development and commercial milestone payments, and royalties upon commercialization Access to dbDNA patent rights enables Pfizer’s rapid production of … Continued
1 March 2022
Touchlight and Versameb announce GMP manufacturing supply agreement
Versameb moves forward with its lead asset towards clinical development with an Innovative synthetic doggybone DNA technology which increases quality and yield of mRNA therapeutics production Hampton, UK, Basel, Switzerland – 1 March 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a development and manufacturing … Continued
8 February 2022
AskBio and Touchlight Restructure Joint Venture
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight, a biotechnology company pioneering enzymatic DNA production, have announced a revised structure to their former joint venture, Touchlight AAV. Under the revised arrangement implemented on 1 February 2022, both parties benefit from co-exclusive rights … Continued
22 November 2021
Touchlight Ranked Number Four Fastest Growing Technology Company in the UK in the 2021 Deloitte Technology Fast 50
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced that it ranked number 4 in the 2021 Deloitte UK Technology Fast 50, a ranking of the 50 fastest-growing technology companies in the UK. Rankings are based on percentage revenue growth over the last four years. Touchlight grew 11,421 … Continued
15 October 2021
Touchlight to break ground on world’s highest-capacity DNA manufacturing facility
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK. The project will include the repair and renovation of a key remaining part of the Morelands and Riverdale Buildings, a … Continued
11 October 2021
Touchlight expands commercial team amid rapid company growth
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has announced the appointment of three new hires to expand the capabilities of its growing commercial team. Robin Bodicoat joins as Head of Marketing, Rhona McIntyre as Head of Sales for Europe, and Julie Foster as Head of Sales for North … Continued